Bristol Myers Current Ratio vs. Beta

BMY Stock  USD 48.93  0.63  1.30%   
Based on Bristol Myers' profitability indicators, Bristol Myers Squibb is performing exceptionally good at this time. It has a great probability to showcase excellent profitability results in May. Profitability indicators assess Bristol Myers' ability to earn profits and add value for shareholders.
 
Current Ratio  
First Reported
2010-12-31
Previous Quarter
1.4270955
Current Value
1.96
Quarterly Volatility
0.98166148
 
Credit Downgrade
 
Yuan Drop
 
Covid
At this time, Bristol Myers' Price To Sales Ratio is fairly stable compared to the past year. Days Sales Outstanding is likely to rise to 129.98 in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.01 in 2024. At this time, Bristol Myers' Operating Income is fairly stable compared to the past year. Total Other Income Expense Net is likely to rise to about 1.5 B in 2024, whereas Accumulated Other Comprehensive Income is likely to drop (1.6 B) in 2024.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.80.7624
Sufficiently Up
Slightly volatile
Operating Profit Margin0.250.3831
Way Down
Pretty Stable
For Bristol Myers profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Bristol Myers to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Bristol Myers Squibb utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Bristol Myers's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Bristol Myers Squibb over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Is Bristol Myers' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myers. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myers listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.09)
Dividend Share
2.31
Earnings Share
3.86
Revenue Per Share
21.753
Quarterly Revenue Growth
0.006
The market value of Bristol Myers Squibb is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myers' value that differs from its market value or its book value, called intrinsic value, which is Bristol Myers' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myers' market value can be influenced by many factors that don't directly affect Bristol Myers' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bristol Myers' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bristol Myers is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myers' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Bristol Myers Squibb Beta vs. Current Ratio Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Bristol Myers's current stock value. Our valuation model uses many indicators to compare Bristol Myers value to that of its competitors to determine the firm's financial worth.
Bristol Myers Squibb is rated below average in current ratio category among related companies. It is rated fifth in beta category among related companies totaling about  0.27  of Beta per Current Ratio. The ratio of Current Ratio to Beta for Bristol Myers Squibb is roughly  3.64 . At this time, Bristol Myers' Current Ratio is fairly stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value Bristol Myers by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Bristol Myers' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bristol Myers' earnings, one of the primary drivers of an investment's value.

Bristol Beta vs. Current Ratio

Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Bristol Myers

Current Ratio

 = 

Current Asset

Current Liabilities

 = 
1.42 X
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.

Bristol Myers

Beta

 = 

Covariance

Variance

 = 
0.39
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.

Bristol Beta Comparison

Bristol Myers is currently under evaluation in beta category among related companies.

Beta Analysis

As returns on the market increase, Bristol Myers' returns are expected to increase less than the market. However, during the bear market, the loss of holding Bristol Myers is expected to be smaller as well.

Bristol Myers Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Bristol Myers, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Bristol Myers will eventually generate negative long term returns. The profitability progress is the general direction of Bristol Myers' change in net profit over the period of time. It can combine multiple indicators of Bristol Myers, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-1.5 B-1.6 B
Operating Income17.2 B18.1 B
Income Before Tax8.4 B4.2 B
Total Other Income Expense Net1.4 B1.5 B
Net IncomeB8.4 B
Income Tax Expense400 M380 M
Net Income Applicable To Common Shares5.7 BB
Net Income From Continuing Ops8.3 B8.7 B
Non Operating Income Net Other-662.4 M-629.3 M
Net Interest Income-1.1 B-1.2 B
Interest Income2.1 B2.2 B
Change To Netincome-970.2 M-921.7 M
Net Income Per Share 3.88  4.07 
Income Quality 1.72  1.02 
Net Income Per E B T 0.95  0.64 

Bristol Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Bristol Myers. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Bristol Myers position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Bristol Myers' important profitability drivers and their relationship over time.

Use Bristol Myers in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol Myers position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myers will appreciate offsetting losses from the drop in the long position's value.

Bristol Myers Pair Trading

Bristol Myers Squibb Pair Trading Analysis

The ability to find closely correlated positions to Bristol Myers could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bristol Myers when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bristol Myers - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bristol Myers Squibb to buy it.
The correlation of Bristol Myers is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bristol Myers moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bristol Myers Squibb moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bristol Myers can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Bristol Myers position

In addition to having Bristol Myers in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Tech Funds Thematic Idea Now

Tech Funds
Tech Funds Theme
Funds or Etfs that invest in companies involved in research, development, testing, or distribution of technologically based goods and services. The Tech Funds theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Tech Funds Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Bristol Myers Squibb offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bristol Myers' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bristol Myers Squibb Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bristol Myers Squibb Stock:

Complementary Tools for Bristol Stock analysis

When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
To fully project Bristol Myers' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Bristol Myers Squibb at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Bristol Myers' income statement, its balance sheet, and the statement of cash flows.
Potential Bristol Myers investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Bristol Myers investors may work on each financial statement separately, they are all related. The changes in Bristol Myers's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Bristol Myers's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.